0000000000177297
AUTHOR
Anne Chauchereau
Elaboration of a method to categorize substances of interest as regards to their potential endocrine disrupting activity: assessment and categorization of prioritized substances
EDCs are substances that alter function(s) of the endocrine system and consequently cause adverse health effects. The endocrine system consists of many cells and tissues that interact with each other and the rest of the body by means of hormones. This system is responsible for controlling a large number of processes in the body from gamete formation, to conception and early developmental processes such as organogenesis, and to most tissue and organ functions throughout life. EDCs interfere with endocrine function by many ways and, in doing so, lead to adverse effects on the health of humans and/or wildlife. Some of the observed health effects associated with EDCs include, butare not limited…
Elaboration of a list of substances of interest as regards to a potential endocrine activity and prioritisation strategy for assessment
Endocrine Disruptor Chemicals (EDCs) are substances that alter function(s) of the endocrine system and consequently cause adverse health effects. The endocrine system consists of many cells and tissues that interact with each other and the rest of the body by means ofhormones. This system is responsible for controlling a large number of processes in the body from gamete formation, to conception and early developmental processes such as organogenesis, and to most tissue and organ functions throughout life. EDCs interfere withendocrine function by many ways and, in doing so, lead to adverse effects on the health of humans and/or wildlife. Some of the observed health effects associated with ED…
Abstract 1138: The protein disulfide isomerase inhibitor XCE853 inhibits in vitro, ex-vivo and in vivo growth of human tumors
Abstract Protein disulfide isomerase (PDI) is a chaperone protein that regulates oxidative protein folding as well as cell viability. Increased PDI levels have been documented in a variety of human cancers associated with a poor overall survival, including ovarian, prostate, brain and lung cancers. Inhibition of PDI activity leads to apoptosis in cancer, suggesting that PDI is a promising druggable target. XCE853 is a synthetic small molecule displaying an excellent docking with the catalytic domain of the human PDI. XCE853 inhibits in vitro recombinant PDI enzymatic activity. In addition, the proliferation of a large panel of human tumor cells is blocked by XCE853 with IC50s in the nanomol…